11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
TLR2 helps control hair growth and regeneration, and its reduction with age or obesity can impair hair growth.
19 citations
,
June 1999 in “Steroids” Different halogens on progesterone derivatives can either block or mimic male hormone effects, depending on their type and amount.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
July 2025 in “Journal of Investigative Dermatology” γδ T cells can prevent and treat alopecia areata, offering a new therapy option.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
9 citations
,
September 2010 in “Immunology Endocrine & Metabolic Agents - Medicinal Chemistry” Sex hormones influence immune responses and may help treat diseases.
November 2022 in “Journal of Investigative Dermatology” Statins may help treat alopecia areata by reducing harmful immune interactions.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
88 citations
,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Thymic stromal lymphopoietin (TSLP) promotes hair growth by stimulating specific skin cells.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
July 1993 in “Inpharma Weekly” Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
October 2025 in “Transactions on Materials Biotechnology and Life Sciences” Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.
84 citations
,
February 2015 in “Experimental Dermatology” PPARγ is crucial for skin health but can have both beneficial and harmful effects.
75 citations
,
March 1999 in “Fertility and sterility” Finasteride, CPA, and flutamide are all equally effective in reducing excessive hair growth in women.
24 citations
,
March 2016 in “Journal of Investigative Dermatology” TIP39 and PTH2R help control calcium levels and skin cell development.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.
5 citations
,
June 2015 in “British Journal of Dermatology” A certain medication improved severe itching in a boy with liver and bowel disease by reducing histamine levels, suggesting a new treatment target.
Combining systemic steroids and dithranol can effectively regrow hair in severe alopecia areata.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
47 citations
,
March 2004 in “European journal of endocrinology” Spironolactone plus finasteride reduces hirsutism more effectively.